글루카곤 시장 규모, 점유율 및 성장 분석 : 적응증별, 투여 경로별, 제제별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Global Glucagon Market size was valued at USD 644.48 Million in 2024 and is poised to grow from USD 683.15 Million in 2025 to USD 1088.84 Million by 2033, growing at a CAGR of 6% during the forecast period (2026-2033).

The global glucagon market is experiencing significant growth, driven by the increasing prevalence of diabetes and the rising need for effective management of severe hypoglycemia. This growth is fueled by the widespread adoption of emergency injectable devices and advancements in nasal glucagon formulations, which enhance patient accessibility and outcomes. Efforts to educate healthcare professionals and patients about prompt responses to hypoglycemic episodes are further amplifying market demand. Additionally, continuous innovations in drug delivery systems and supportive government healthcare initiatives contribute to the market's expansion. However, challenges such as high treatment costs, limited awareness in underserved regions, apprehensions regarding side effects, and stringent regulatory requirements, alongside dependence on cold-chain logistics, present substantial barriers to market penetration and scalability.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Glucagon market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Glucagon Market Segments Analysis

Global Glucagon Market is segmented by Indication, Route of Administration, Formulation, End-User and region. Based on Indication, the market is segmented into Hypoglycemia, Diabetic Ketoacidosis and Metabolic Disease Trials. Based on Route of Administration, the market is segmented into Intravenous, Subcutaneous and Intramuscular. Based on Formulation, the market is segmented into Injectable Kits, Liquid Stable Autoinjectors, Nasal Powder and Liquid Stable Vials. Based on End-User, the market is segmented into Hospitals, Clinic, Drug Stores, Online Pharmacies and Home Care Setting. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Glucagon Market

The rising prevalence of diabetes, particularly type 1 diabetes, worldwide significantly propels the expansion of the glucagon market. Individuals reliant on insulin are at constant risk of severe hypoglycemia, necessitating prompt intervention. This urgent healthcare requirement heightens the demand for glucagon treatments in various settings, including hospitals, clinics, and homecare environments. As awareness grows regarding the critical need for effective glucagon responses to hypoglycemic episodes, the market continues to experience substantial growth, driven by the necessity to ensure patient safety and effective management of diabetes-related emergencies.

Restraints in the Global Glucagon Market

The development and production of innovative glucagon delivery systems, like prefilled autoinjectors and nasal powders, entails significant costs, which can be a barrier to their widespread adoption. This financial burden is particularly pronounced in low- and middle-income countries, where high prices may deter their utilization. Moreover, the escalation in costs impacts healthcare systems and insurance providers, consequently hindering the broader distribution and accessibility of these advanced treatment options. Such economic constraints pose a challenge to the overall growth and efficacy of the global glucagon market, limiting its potential to improve patient outcomes across diverse demographics.

Market Trends of the Global Glucagon Market

The Global Glucagon market is witnessing a robust growth trajectory, driven by significant technological advancements in drug delivery systems. Innovations such as liquid-stable formulations, nasal sprays, and autoinjectors are revolutionizing how glucagon is administered, enhancing emergency response and patient compliance. These advancements eliminate the necessity for reconstitution, improve shelf stability, and facilitate straightforward administration, making it more accessible for patients during hypoglycemic episodes. With an increasing focus on user-friendly solutions that prioritize ease of use and reliability, the market is set for continued expansion as healthcare providers and patients alike embrace these cutting-edge delivery methods.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies

Global Glucagon Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Hypoglycemia
• Diabetic Ketoacidosis
• Metabolic Disease Trials

Global Glucagon Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Intravenous
• Subcutaneous
• Intramuscular

Global Glucagon Market Size by Formulation & CAGR (2026-2033)

• Market Overview
• Injectable Kits
• Liquid Stable Autoinjectors
• Nasal Powder
• Liquid Stable Vials

Global Glucagon Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Clinic
• Drug Stores
• Online Pharmacies
• Home Care Setting

Global Glucagon Market Size & CAGR (2026-2033)

• North America (Indication, Route of Administration, Formulation, End-User)
  • US
  • Canada
• Europe (Indication, Route of Administration, Formulation, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Indication, Route of Administration, Formulation, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Indication, Route of Administration, Formulation, End-User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Indication, Route of Administration, Formulation, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Sun Pharmaceuticals Industries
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zealand Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• KemPharm
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceuticals Industries
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Reddy's Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Xeris Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations